Business
Bausch + Lomb sells eye-health products across Vision Care, Pharmaceuticals, and Surgical segments.
Bausch + Lomb grew revenue and drew broad insider purchases, but losses, negative FCF, and high debt kept pressure on the profile.
The read at a glance✓ Audited against SEC data
- Business mix — Eye-health productsNote
- Revenue — Revenue up 6.5%OK
- Loss — Net loss widened to $360MWatch
- FCF — FCF fell to -$66MWatch
- Debt — Debt up to $5.05BWatch
- Insiders — 9 purchases / 0 salesOK
- Accounting — Altman-Z distress; other screens unavailableWatch
Where the revenue comes from
Fiscal 2025, as Bausch & Lomb Corp reports it. History and quarterly detail are in the app.
- Vision Care$2.9B
- Pharmaceuticals$1.3B
- Surgical$894.0M
Leadership changes
From Bausch & Lomb Corp's own filings, the day they're filed.
- Eduardo C. Alfonso · directors · departureeff. 2026-01-01
- Steven H. Collis · directors · departureeff. 2026-01-01
- Brett Icahn · directors · departureeff. 2025-08-14
Latest filings
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-07-29
- 8-K · Company announcement2026-07-29
- 8-K · Company announcement2026-05-20
- 8-K · Company announcement2026-04-29
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Bausch & Lomb Corp, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.